Gilead Sciences’ (GILD) Hold Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Gilead Sciences (NASDAQ:GILD) in a research report released on Monday morning, AnalystRatings.com reports.

“Gilead reported $5.28B in 1Q19 total revenue, in line w/ our $5.27B and consensus $5.3B ests. Product sales were $5.20B (-8% q/q), matching our $5.16B and consensus $5.2B ests. Mgmt had guided for 12-14% sequential decline. All annual guidance unch. Non-GAAP EPS $1.76 was above our $1.64 and consensus $1.61 ests. New CEO O’Day outlined priorities (Strengthen pipeline [internal and external business development]; Ensure optimal commercial delivery; and Reassess organizational structure [‘evolution not revolution’]) and announced that Kite will operate as a separate business unit w/ a new CEO reporting directly to O’Day. Filgotinib MAA to be submitted 3Q19, but no update yet on strategy/ timing for NDA submission. NASH ATLAS drug combination trial results expected 4Q19 (unch). HOLD.”,” the firm’s analyst commented.

Other equities analysts have also issued reports about the company. Zacks Investment Research upgraded Gilead Sciences from a hold rating to a buy rating and set a $69.00 price target on the stock in a research report on Tuesday, April 23rd. BidaskClub upgraded Gilead Sciences from a sell rating to a hold rating in a research report on Friday, May 3rd. ValuEngine upgraded Gilead Sciences from a sell rating to a hold rating in a research report on Wednesday, May 1st. Cowen restated a buy rating on shares of Gilead Sciences in a research report on Friday, May 3rd. Finally, Oppenheimer set a $85.00 price target on Gilead Sciences and gave the stock a buy rating in a research report on Tuesday, March 19th. Nine investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $81.61.

Shares of Gilead Sciences stock opened at $66.13 on Monday. The company has a debt-to-equity ratio of 1.19, a quick ratio of 3.56 and a current ratio of 3.65. The stock has a market cap of $84.31 billion, a PE ratio of 10.75, a PEG ratio of 0.89 and a beta of 1.14. Gilead Sciences has a 12 month low of $60.32 and a 12 month high of $79.61.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.53 by $0.23. The firm had revenue of $5.28 billion for the quarter, compared to analyst estimates of $5.29 billion. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The company’s revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the company earned $1.48 EPS. Research analysts forecast that Gilead Sciences will post 6.2 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.81%. The ex-dividend date is Thursday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 40.98%.

In other Gilead Sciences news, Director Gayle E. Wilson sold 19,068 shares of the stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total value of $1,279,081.44. Following the completion of the sale, the director now owns 143,567 shares in the company, valued at approximately $9,630,474.36. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director John Francis Cogan sold 2,700 shares of the stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $64.14, for a total value of $173,178.00. Following the completion of the sale, the director now owns 57,560 shares of the company’s stock, valued at approximately $3,691,898.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 47,670 shares of company stock valued at $3,142,526. Company insiders own 0.20% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp increased its position in Gilead Sciences by 95.7% during the 4th quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 554,083 shares of the biopharmaceutical company’s stock valued at $34,658,000 after buying an additional 271,000 shares in the last quarter. Chilton Capital Management LLC increased its position in Gilead Sciences by 3.5% during the 4th quarter. Chilton Capital Management LLC now owns 16,468 shares of the biopharmaceutical company’s stock valued at $1,030,000 after buying an additional 555 shares in the last quarter. Nicholas Company Inc. increased its position in Gilead Sciences by 2.7% during the 4th quarter. Nicholas Company Inc. now owns 506,760 shares of the biopharmaceutical company’s stock valued at $31,697,000 after buying an additional 13,500 shares in the last quarter. Sectoral Asset Management Inc increased its position in Gilead Sciences by 59.6% during the 4th quarter. Sectoral Asset Management Inc now owns 424,890 shares of the biopharmaceutical company’s stock valued at $26,577,000 after buying an additional 158,750 shares in the last quarter. Finally, AIMZ Investment Advisors LLC increased its position in Gilead Sciences by 39.9% during the 4th quarter. AIMZ Investment Advisors LLC now owns 53,738 shares of the biopharmaceutical company’s stock valued at $3,361,000 after buying an additional 15,333 shares in the last quarter. Institutional investors and hedge funds own 80.07% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Recommended Story: Book Value Per Share in Stock Trading

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.